Search Result

Results for "

CB2+receptor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Aldehyde Dehydrogenase (ALDH) (1) ANGPTL (1) Apoptosis (1) Biochemical Assay Reagents (1) Cannabinoid Receptor (68) Caspase (2) Cholinesterase (ChE) (1) Drug Intermediate (1) Drug Isomer (1) Endogenous Metabolite (11) Environmental Pollutants (1) GlyT (2) HIF/HIF Prolyl-Hydroxylase (1) Interleukin Related (1) Isotope-Labeled Compounds (5) Orphan GPCR (1) Potassium Channel (1) PPAR (1) Reference Standards (3) TRP Channel (2) VEGFR (1)
By Research Areas:	Cancer (14) Cardiovascular Disease (1) Endocrinology (1) Infection (3) Inflammation/Immunology (19) Metabolic Disease (15) Neurological Disease (40)
Click Chemistry:	Azide (2)

Inhibitors & Agonists

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N1415

β-Caryophyllene Maximum Cited Publications 6 Publications Verification (-)-(E)-Caryophyllene; (−)-β-caryophyllene; (−)-trans-Caryophyllene	Environmental Pollutants Endogenous Metabolite Cannabinoid Receptor	Infection Neurological Disease Cancer
β-Caryophyllene is a *CB2 receptor* agonist.

HY-13439

SR144528 Maximum Cited Publications 6 Publications Verification	Cannabinoid Receptor	Neurological Disease
SR144528 is a potent and selective *CB2 receptor* antagonist with a K_i of 0.6 nM.

HY-13505

AM281 1 Publications Verification	Cannabinoid Receptor	Neurological Disease
AM281 is a selective CB1 receptor antagonist with an IC₅₀ of 9.91 nM. AM281 inhibits CB2 receptor with an IC₅₀ of 13000 nM .

HY-103332

N-Arachidonylglycine 1 Publications Verification NA-Gly	GlyT Endogenous Metabolite	Inflammation/Immunology
N-Arachidonylglycine (NA-Gly), a carboxylic analog of the endocannabinoid anandamide (AEA), is a GPR18 agonist (EC₅₀ = 44.5 nM). Unlike AEA, N-Arachidonylglycine has no activity at either CB1 or CB2 receptors. N-Arachidonylglycine inhibits *GLYT2* (IC₅₀ = 5.1 μM). N-Arachidonylglycine also is an effective activator of endometrial cell migration ^[2].

HY-10871

Otenabant 2 Publications Verification CP-945598	Cannabinoid Receptor	Metabolic Disease
Otenabant is a potent and selective *cannabinoid receptor* CB1 antagonist with K_i** of 0.7 nM, exhibits 10,000-fold greater selectivity against human CB2 receptor.

HY-103325

JTE-907	Cannabinoid Receptor TRP Channel Interleukin Related ANGPTL VEGFR	Metabolic Disease Inflammation/Immunology
JTE-907 is a selective and orally active cannabinoid *CB2* receptor inverse agonist and exerts anti-inflammatory effects. JTE-907 upregulates IL-6, MCP-1, IL-1β, VEGF, ANGPTL4, and TRPV1 in mature adipocytes. JTE-907 downregulates CB1, MCP-1, and IL-1β in preadipocytes. JTE-907 inhibits ear swelling in mice. JTE-907 reverses the protective effects of CB2 agonists and Anandamide (HY-10863) against cytokine-evoked colonic mucosal damage. JTE-907 can be used for the research of allergic dermatitis, obesity, and colitis ^[2] .

HY-100488

Bay 59-3074	Cannabinoid Receptor	Cancer
Bay 59-3074 is a selective cannabinoid *CB₁/CB₂ receptor* partial agonist with K_i values of 48.3 and 45.5 nM at human CB₁ and *CB₂* receptors, respectively. Bay 59-3074 has analgesic properties .

HY-15420

BML-190 Indomethacin morpholinylamide; IMMA	Cannabinoid Receptor	Cancer
BML-190(IMMA) is a potent and selective CB2 receptor ligand (Ki values are 435 nM and > 2 μM for CB2 and CB1 respectively).

HY-112340

CB1 antagonist 4	Cannabinoid Receptor	Neurological Disease Metabolic Disease
CB1 antagonist 4 (compound 8) is a selective cannabinoid receptor 1 (CB1) inverse agonist with an IC₅₀ of 8.5 nM for human CB1. CB1 antagonist 4 shows selective for CB1 over CB2 receptors (IC₅₀ of 604.9 nM). CB1 antagonist 4 inhibits GTP binding to CB1-overexpressing cell membranes with an EC₅₀ of 18.5 nM .

HY-132217

CB2 receptor agonist 2	Cannabinoid Receptor	Neurological Disease
CB2 receptor agonist 2 is a potent and selective agonist for the *CB2* (cannabinoid type 2) receptor with a K_i of 8.5 nM. CB2 receptor agonist 2 has high affinity and selectivity for *CB2* .

HY-N1415S

β-Caryophyllene-d2	Cannabinoid Receptor Endogenous Metabolite	Infection Neurological Disease Cancer
β-Caryophyllene-d₂ is deuterium labeled β-Caryophyllene. β-Caryophyllene is a CB2 receptor agonist.

HY-113070

Dihomo-γ-Linolenoyl Ethanolamide	Cannabinoid Receptor Endogenous Metabolite	Neurological Disease
Dihomo-γ-Linolenoyl Ethanolamide, an endocannabinoid, is a *cannabinoid (CB) receptor* agonist with K_is of 857 nM and 598 nM for human recombinant CB1 and *CB2 receptors, respectively .*

HY-119104

AZD1940 1 Publications Verification	Cannabinoid Receptor	Neurological Disease
AZD1940 is an orally active, high affinity cannabinoid CB1/CB2 receptor agonist with pK_i values of 7.93 and 9.06 for human CB1R and *CB2R*, respectively. AZD1940 shows a robust analgesia action ^[2].

HY-146134

PGN36	Cannabinoid Receptor	Neurological Disease Inflammation/Immunology
PGN36 is a selective cannabinoid CB2 receptor (CB2R) antagonist with K_is of 0.09 µM and >40 µM for CB2R and CB1R, respectively. PGN36 abolishes the increase in collagen type I gene expression by the inducer of bone activity. PGN36 is able to cross the blood-brain barrier. PGN36 can be used for the study of frontotemporal dementia (FTD) ^[2].

HY-113421

Linoleoyl ethanolamide Linoleic acid monoethanolamide	Cannabinoid Receptor	Neurological Disease
Linoleoyl ethanolamide (Linoleic acid monoethanolamide) is classified as a fatty acid ethanolamide. Linoleoyl ethanolamide only weakly binds G-protein-coupled cannabinoid receptors of type-1（CB1）and CB2 receptors, and inhibits the binding of ^[3H]CP-55,940 with K_is of 10 and 25 μM, respectively. Linoleoyl ethanolamide is 4-fold less potent than anandamide at causing catalepsy in mice and it does not prolong sleep time ^[2].

HY-124283A

LEI-101	Cannabinoid Receptor	Neurological Disease
LEI-101 is a potent, selective, and orally bioavailable cannabinoid CB2 receptor agonist, with a pEC₅₀ of 8 for hCB2, and a pK_i of less than 4 for hERG. LEI-101 is ~100-fold more potent in binding to CB2 receptors than to CB1 receptors ^[2].

HY-N1415R

β-Caryophyllene (Standard) Maximum Cited Publications 6 Publications Verification (-)-(E)-Caryophyllene(Standard); (−)-β-caryophyllene(Standard); (−)-trans-Caryophyllene (Standard)	Reference Standards Cannabinoid Receptor Endogenous Metabolite	Infection Neurological Disease Cancer
β-Caryophyllene (Standard) is the analytical standard of β-Caryophyllene. This product is intended for research and analytical applications. β-Caryophyllene is a *CB2 receptor* agonist.

HY-128872

Etrinabdione EHP-101; VCE-004.8	PPAR Cannabinoid Receptor HIF/HIF Prolyl-Hydroxylase	Metabolic Disease Inflammation/Immunology
Etrinabdione (EHP-101; VCE-004.8) is an orally active, specific PPARγ and *CB₂* receptor dual agonist. Etrinabdione inhibits prolyl-hydroxylases (PHDs) and activates the HIF pathway. Etrinabdione, a semi-synthetic multitarget cannabinoquinoid, has potent anti-inflammatory activity. Etrinabdione attenuates adipogenesis and prevents diet-induced obesity ^[2].

HY-122964

URB447	Cannabinoid Receptor	Metabolic Disease
URB447 is a peripherally restricted CB₁ cannabinoid antagonist (IC₅₀: 313 nM and 41 nM for rat CB1 and human CB2 receptor respectively ). URB447 lowers food intake and body-weight gain in mice without entering the brain or antagonizing central CB₁-dependent responses. URB447 can be used for research of obesity .

HY-12761

A-836339	Cannabinoid Receptor	Cardiovascular Disease Others Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
A-836339 is a selective *CB2* receptor agonist, with Ki values of 0.4 nM and 0.8 nM in humans and rats, respectively. A-836339 exhibits multiple effects such as analgesia, gastric protection, anti-inflammation, and antioxidant activity. A-836339 produces antinociceptive and analgesic activities by activating *CB2* receptors in the dorsal root ganglia and spinal cord. A-836339 can also exert gastric protective effects through anti-inflammatory mechanisms (reducing TNF-α and IL-1β) and antioxidant mechanisms (enhancing the activities of CAT and SOD, and reducing H₂O₂). Radioactively labeled A-836339 can serve as a CB2-specific radioligand for autoradiography and PET imaging. A-836339 can be used in research on inflammatory pain, neuropathic pain, gastric ulcers, cerebral ischemia, etc ^[2] .

HY-113591

CB2 receptor agonist 10	Cannabinoid Receptor	Others
CB2 receptor agonist 10 is a *CB2* receptor agonist with a K_i of 3.7 nM for *hCB2, a K_i* of 110 nM for hCB1, and an EC₅₀ of 0.52 nM for *hCB2* .

HY-N1415S1

β-Caryophyllene-13C,d2 (-)-(E)-Caryophyllene-¹³C,d₂; (−)-β-caryophyllene-¹³C,d₂; (−)-trans-Caryophyllene-¹³C,d₂	Endogenous Metabolite Cannabinoid Receptor Isotope-Labeled Compounds	Cancer
β-Caryophyllene- ¹³C,d₂ is ¹³C and deuterated labeled β-Caryophyllene (HY-N1415). β-Caryophyllene is a CB2 receptor agonist .

HY-124089

Eicosapentaenoyl ethanolamide	Cannabinoid Receptor	Metabolic Disease
Eicosapentaenoyl ethanolamide, an omega-3 fatty acid, is one of N-acylethanolamines (NAEs). Eicosapentaenoyl ethanolamide is cannabinoid CB1/CB2 receptor agonist. Eicosapentaenoyl ethanolamide acts as a metabolic signal. Eicosapentaenoyl ethanolamide inhibits dietary restriction (DR)-induced lifespan extension in wild type animals and suppresses lifespan extension in a TOR pathway mutant ^[2].

HY-159161

PSB-CB-27	Orphan GPCR	Inflammation/Immunology Cancer
PSB-CB-27 is a potent and selective GPR18 inhibitor with an IC₅₀ of 0.65 μM. PSB-CB-27 shows selectivity over Human GPR55, Human CB1 receptor, and Human CB2 receptor. PSB-CB-27 leads to a complete blockade of Δ9-Tetrahydrocannabinol (THC)-induced GPR18 activation. PSB-CB-27 can be used for inflammatory diseases and cancer immunotherapy research .

HY-113421S

Linoleoyl ethanolamide-d4	Isotope-Labeled Compounds Cannabinoid Receptor	Neurological Disease
Linoleoyl ethanolamide-d4 is a deuterated labeled Linoleoyl ethanolamide . Linoleoyl ethanolamide (Linoleic acid monoethanolamide) is classified as a fatty acid ethanolamide. Linoleoyl ethanolamide only weakly binds G-protein-coupled cannabinoid receptors of type-1（CB1）and CB2 receptors, and inhibits the binding of ^[3H]CP-55,940 with K_is of 10 and 25 μM, respectively. Linoleoyl ethanolamide is 4-fold less potent than anandamide at causing catalepsy in mice and it does not prolong sleep time ^[2] .

HY-10871A

Otenabant Hydrochloride CP 945598 Hydrochloride	Cannabinoid Receptor	Metabolic Disease
Otenabant Hydrochloride is a potent and selective *cannabinoid receptor* CB1 antagonist with K_i** of 0.7 nM, exhibits 10,000-fold greater selectivity against human CB2 receptor.

HY-110065

SER-601	Cannabinoid Receptor	Neurological Disease
SER-601 is a potent and selective peripheral cannabinoid (CB2) receptor agonist with a K_i of 6.3 nM. SER-601 has analgesic and antidiabetic properties and can be used for relevant research .

HY-178943

Neuroprotective agent 15	Cholinesterase (ChE) Cannabinoid Receptor Aldehyde Dehydrogenase (ALDH) Caspase Apoptosis	Neurological Disease
Neuroprotective agent 15 (Compound 3e) is a neuroprotective agent. Neuroprotective agent 15 is a selective butyrylcholinesterase (BChE) inhibitor, with IC₅₀ values of 2.6 and 114.3 μM for BChE and AChE respectively. Neuroprotective agent 15 has cannabinoid CB2 receptor (CB2 receptor) agonistic activity. Neuroprotective agent 15 can reduce cell death, LDH release and Caspase-3/7 activity, and inhibit apoptosis. Neuroprotective agent 15 can reduce the formation of superoxide free radicals, maintain cell morphology, and significantly lower oxidative stress levels. Neuroprotective agent 15 can be used in the research of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease .

HY-110194

Virodhamine TFA	Endogenous Metabolite Cannabinoid Receptor	Neurological Disease
Virodhamine TFA is an endocannabinoid, it regulates neurotransmission by activating the cannabinoid (CB) receptors. Virodhamine is an antagonist of CB1 receptor and an agonist of CB2 receptor. Virodhamine TFA induces megakaryocytic differentiation by triggering MAPK signaling and ROS production. Virodhamine TFA can be used for the research of various neurological disorders such as Alzheimer's and Parkinson's diseases ^[2].

HY-168734

CB2 receptor agonist 9	Cannabinoid Receptor	Inflammation/Immunology
CB2 receptor agonist 9 (Compound 33) is an orally active agonist for *cannabinoid receptor* 2** (CB2 receptor) with an EC₅₀ of 16.2 nM. CB2 receptor agonist 9 inhibits the expression of TNF-α, IL-1β and IL-6, exhibits anti-inflammatory efficacy in DDS (HY-116282)-induced mouse acute colitis model .

HY-W127407

Glycerophospho-N-arachidonoyl ethanolamine	Biochemical Assay Reagents	Others
Glycerophospho-N-Arachidonoyl Ethanolamine is a N-acylated ethanolamines (NAEs). Most NAEs are naturally occurring lipids with diverse biological activities. Different types of NAE can be derived from glycerophosphate-linked precursors through the activity of glycerophosphodiesterase 1 (GDE1). Glycerophosphate-N-Arachidonoyl Ethanolamine is the precursor of Anandamide (AEA), also known as Anandamide. AEA is an endocannabinoid neurotransmitter that binds to central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptors. It inhibits the specific binding of [3H]-HU-243 to synaptosomal membranes with a Ki value of 52 nM compared to 46 nM for δ9-THC.

HY-173083

MDA7	Cannabinoid Receptor	Neurological Disease
MDA7 is the selective agonist for *cannabinoid receptor* 2 with EC₅₀** of 128 nM and 67.4 nM in human CB2 receptor and rat CB2 receptor. MDA7 exhibits good affinity to human CB2 receptor and rat CB2 receptor with K_i of 422 nM and 238 nM. MDA7 exhibits analgesic activity in rats models .

HY-W751734

HU 433	Cannabinoid Receptor	Others Neurological Disease Inflammation/Immunology
HU 433 is a synthetic cannabinoid *CB2* receptor agonist and is the enantiomer of HU 308 (HY-161510). HU 433 exerts its anti-inflammatory and neuroprotective effects by binding to *CB2* receptors. HU 433 can be used in the study of neuroinflammation and retinal diseases .

HY-128040

Virodhamine hydrochloride	Endogenous Metabolite Cannabinoid Receptor	Neurological Disease
Virodhamine (hydrochloride) is a cannabinoid CB1 receptor partial agonist and cannabinoid *CB2* receptor full agonist .

HY-133533

O-2050	Cannabinoid Receptor	Neurological Disease
O-2050 is a high affinity cannabinoid CB₁ receptor antagonist with a K_i of 2.5 nM. O-2050 inhibits cannabinoid CB₂ receptor (K_i=0.2 nM). O-2050 can cause locomotor stimulation in mice .

HY-163825

RNB-61	Cannabinoid Receptor	Neurological Disease Inflammation/Immunology
RNB-61 is an oral active agonist of cannabinoid CB2 receptor (CB2R), with the K_i ranging from 0.13 nM to 1.81 nM. RNB-61 has nephroprotective and/or antifibrotic effects. RNB-61 has negligible penetration into the brain .

HY-123410

KM-233	Cannabinoid Receptor	Cancer
KM-233 is a classical cannabinoid with good blood brain barrier penetration. KM-233 possesses a selective affinity for the CB2 receptors relative to THC. KM-233 is effective at reducing U87 glioma tumor burden, and can be used for glioma research .

HY-116380

CB2 receptor antagonist 5	Cannabinoid Receptor	Others
CB2 receptor antagonist 5 (compound 4A) is a ligand of CB2 receptor with antagonist effect .

HY-14160

CB2 receptor agonist 7	Cannabinoid Receptor	Neurological Disease Cancer
CB2 receptor agonist 7 (Compound 5B) is a cannabinoid 2 (CB2) receptor agonist with blood-brain barrier permeability .

HY-168338

CB2 receptor agonist 8	Cannabinoid Receptor Caspase	Cancer
CB2 receptor agonist 8 (Compound 17) is an agonist for *cannabinoid receptor* 2** (CB2 receptor). CB2 receptor agonist 8 exhibits cytotoxicity in cells U87, RPMI 8226, HL-60, and L929 with IC₅₀s of 91.03, 16.29, 23.51 and 564.6 μM, respectively. CB2 receptor agonist 8 activates caspase 3/7, increases the expressions of pro-apoptotic genes BAX, BAD, BIM and tumor suppressor genes p53, and induces apoptosis in U87. CB2 receptor agonist 8 inhibits the migration of U87 .

HY-163394

CB2 receptor agonist 6	Cannabinoid Receptor	Neurological Disease Inflammation/Immunology
CB2 receptor agonist 6 (compound 70) is an agonist of *CB2R, with EC₅₀* of 162 nM. The IC₅₀ values of CB2 receptor agonist 6 are 4.83 μM for CB1R and 0.88 μM for *CB2R. CB2 receptor* agonist 6 is a neuroprotective agent that can be used for the reseach of neurological disease .

HY-155481

CB2 receptor antagonist 3	Cannabinoid Receptor	Neurological Disease
CB2 receptor antagonist 3 (compound (S)-1) is an inverse agonist of the cannabinoid receptor CB2R with Kd=39 nM. CB2 receptor antagonist 3 can be used as a tool to synthesize a variety of CB2R probes .

HY-149645

CB2 receptor antagonist 2	Cannabinoid Receptor	Others
CB2 receptor antagonist 2 (compound 39) is a potent antagonist of *CB2* with an IC₅₀ value of 0.33 μM. CB2 receptor antagonist 2 has strong interactions with L17, W6.48, V6.51, and C7.42 .

HY-155481A

CB2 receptor antagonist 4	Cannabinoid Receptor	Others
CB2 receptor antagonist 4 (compound (R)-1) is a *CB2R*-selective inverse agonist with a K_d value of 39 nM .

HY-107471

CB2 receptor agonist 3 GP2a	Cannabinoid Receptor	Cancer
CB2 receptor agonist 3 is a robust and selective *CB2* cannabinoid agonist with K_is of 7.6 and 900 nM for CB2 and CB1, respectively. CB2 receptor agonist 3 significantly increases P-ERK 1/2 expression in HL-60 cells .

HY-147707

CB2 receptor antagonist 1	Cannabinoid Receptor	Others
Hexyl resorcinol derivative 29 has been proved to be a CB2 selective competitive antagonist / reverse agonist with good potency. Olivanol and 5- (2-methyloctane-2-yl) resorcinol derivatives 23 and 24 showed significant antinociceptive activity. Compound 24 was shown to activate cannabinoid and TRPV1 receptors.

HY-119744

BAY 38-7271	Cannabinoid Receptor	Neurological Disease
BAY 38-7271 is selective and highly potent and cannabinoid *CB₁/CB₂ receptor* agonist, with K_is of 1.85 nM and 5.96 nM for recombinant human CB₁ receptor and CB₂ receptor, respectively. BAY 38-7271 has strong neuroprotective properties .

HY-100328

CB2R-IN-1	Cannabinoid Receptor	Neurological Disease
CB2R-IN-1 is a potent cannabinoid CB₂ receptor inverse agonist with a K_i of 0.9 nM.

HY-108067

SAD448	Cannabinoid Receptor	Others
SAD448 is a CB1 and *CB2 receptor* agonist. SAD448 can lower intraocular pressure (IOP) .

HY-110041

L-759656	Cannabinoid Receptor	Inflammation/Immunology
L-759656 is a selective cannabinoid CB2 receptor agonist, with the K_i of 11.8 nM for the human CB2 receptor. L-759656 potently inhibits Forskolin (HY-15371)-stimulated cyclic AMP production in Chinese Hamster Ovary (CHO) cells, with an EC₅₀ of 3.1 nM. L-759656 can be used for the study of immune-related diseases and inflammatory diseases .

Cat. No.	Product Name	Type

HY-W127407

Glycerophospho-N-arachidonoyl ethanolamine

Biochemical Assay Reagents

Glycerophospho-N-Arachidonoyl Ethanolamine is a N-acylated ethanolamines (NAEs). Most NAEs are naturally occurring lipids with diverse biological activities. Different types of NAE can be derived from glycerophosphate-linked precursors through the activity of glycerophosphodiesterase 1 (GDE1). Glycerophosphate-N-Arachidonoyl Ethanolamine is the precursor of Anandamide (AEA), also known as Anandamide. AEA is an endocannabinoid neurotransmitter that binds to central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptors. It inhibits the specific binding of [3H]-HU-243 to synaptosomal membranes with a Ki value of 52 nM compared to 46 nM for δ9-THC.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N1415

β-Caryophyllene Maximum Cited Publications 6 Publications Verification (-)-(E)-Caryophyllene; (−)-β-caryophyllene; (−)-trans-Caryophyllene	Structural Classification Neurological Disease Classification of Application Fields Anti-aging Plants Endogenous metabolite Infection other families Terpenoids Sesquiterpenes Disease Research Fields Source Classification Cancer	Environmental Pollutants Endogenous Metabolite Cannabinoid Receptor
β-Caryophyllene is a *CB2 receptor* agonist.

HY-103332

N-Arachidonylglycine 1 Publications Verification NA-Gly	Alkaloids Classification of Application Fields Other Alkaloids Endogenous metabolite Inflammation/Immunology Disease Research Fields Source Classification	GlyT Endogenous Metabolite
N-Arachidonylglycine (NA-Gly), a carboxylic analog of the endocannabinoid anandamide (AEA), is a GPR18 agonist (EC₅₀ = 44.5 nM). Unlike AEA, N-Arachidonylglycine has no activity at either CB1 or CB2 receptors. N-Arachidonylglycine inhibits *GLYT2* (IC₅₀ = 5.1 μM). N-Arachidonylglycine also is an effective activator of endometrial cell migration ^[2].

HY-113070

Dihomo-γ-Linolenoyl Ethanolamide	Alkaloids Neurological Disease Classification of Application Fields Other Alkaloids Endogenous metabolite Disease Research Fields Source Classification	Cannabinoid Receptor Endogenous Metabolite
Dihomo-γ-Linolenoyl Ethanolamide, an endocannabinoid, is a *cannabinoid (CB) receptor* agonist with K_is of 857 nM and 598 nM for human recombinant CB1 and *CB2 receptors, respectively .*

HY-113421

Linoleoyl ethanolamide Linoleic acid monoethanolamide	Human Gut Microbiota Metabolites Microorganisms Endogenous metabolite Source Classification	Cannabinoid Receptor
Linoleoyl ethanolamide (Linoleic acid monoethanolamide) is classified as a fatty acid ethanolamide. Linoleoyl ethanolamide only weakly binds G-protein-coupled cannabinoid receptors of type-1（CB1）and CB2 receptors, and inhibits the binding of ^[3H]CP-55,940 with K_is of 10 and 25 μM, respectively. Linoleoyl ethanolamide is 4-fold less potent than anandamide at causing catalepsy in mice and it does not prolong sleep time ^[2].

HY-N1415R

β-Caryophyllene (Standard) Maximum Cited Publications 6 Publications Verification (-)-(E)-Caryophyllene(Standard); (−)-β-caryophyllene(Standard); (−)-trans-Caryophyllene (Standard)	Infection other families Neurological Disease Classification of Application Fields Anti-aging Terpenoids Plants Endogenous metabolite Disease Research Fields Source Classification Cancer	Reference Standards Cannabinoid Receptor Endogenous Metabolite
β-Caryophyllene (Standard) is the analytical standard of β-Caryophyllene. This product is intended for research and analytical applications. β-Caryophyllene is a *CB2 receptor* agonist.

HY-N15177

Δ9-THCB Δ9-Tetrahydrocannabutol	Monophenols Cannabis sativa L Phenols Plants Moraceae Source Classification	Cannabinoid Receptor
Δ9-THCB (Δ9-Tetrahydrocannabutol) has a high affinity for human CB1 and *CB2* receptors with the K_i values of 15 nM and 51 nM, respectively. Δ9-THCB (Δ9-Tetrahydrocannabutol) has analgesic and anti-inflammatory activities and plays partial agonistic effects on CB1 receptor in mice .

Cat. No.	Product Name	Chemical Structure

HY-N1415S

β-Caryophyllene-d2
β-Caryophyllene-d₂ is deuterium labeled β-Caryophyllene. β-Caryophyllene is a CB2 receptor agonist.

HY-N1415S1

β-Caryophyllene-13C,d2
β-Caryophyllene- ¹³C,d₂ is ¹³C and deuterated labeled β-Caryophyllene (HY-N1415). β-Caryophyllene is a CB2 receptor agonist .

HY-113421S

Linoleoyl ethanolamide-d4

Linoleoyl ethanolamide-d4 is a deuterated labeled Linoleoyl ethanolamide . Linoleoyl ethanolamide (Linoleic acid monoethanolamide) is classified as a fatty acid ethanolamide. Linoleoyl ethanolamide only weakly binds G-protein-coupled cannabinoid receptors of type-1（CB1）and CB2 receptors, and inhibits the binding of ^[3H]CP-55,940 with K_is of 10 and 25 μM, respectively. Linoleoyl ethanolamide is 4-fold less potent than anandamide at causing catalepsy in mice and it does not prolong sleep time ^[2] .

HY-124089S

Eicosapentaenoyl ethanolamide-d4

Eicosapentaenoyl ethanolamide-d₄ is the deuterium labeled Eicosapentaenoyl ethanolamide. Eicosapentaenoyl ethanolamide, an omega-3 fatty acid, is one of N-acylethanolamines (NAEs). Eicosapentaenoyl ethanolamide is cannabinoid CB1/CB2 receptor agonist. Eicosapentaenoyl ethanolamide acts as a metabolic signal. Eicosapentaenoyl ethanolamide inhibits dietary restriction (DR)-induced lifespan extension in wild type animals and suppresses lifespan extension in a TOR pathway mutant ^[2].

HY-103332S

N-Arachidonylglycine-d8

N-Arachidonylglycine-d8 is a deuterated labeled N-Arachidonylglycine . N-Arachidonylglycine (NA-Gly), a carboxylic analog of the endocannabinoid anandamide (AEA), is a GPR18 agonist (EC₅₀ = 44.5 nM). Unlike AEA, N-Arachidonylglycine has no activity at either CB1 or CB2 receptors. N-Arachidonylglycine inhibits GLYT2 (IC₅₀ = 5.1 μM). N-Arachidonylglycine also is an effective activator of endometrial cell migration ^[2] .

HY-W770198

2-Linoleoyl glycerol-d5

2-Linoleoyl glycerol-d₅ (2-Monolinolein-d₅; 2-Monolinoleoylglycerol-d₅) is the deuterium labeled 2-Linoleoyl glycerol (HY-130311). 2-Linoleoyl glycerol (2-Monolinolein; 2-Monolinoleoylglycerol) is a monoacylglycerol that is an antagonist and partial agonist at the type 1 cannabinoid CB1 receptor. The potency of 2-Linoleoyl glycerol can be enhanced by JZL195 (HY-15250), an inhibitor of FAAH and MAGL, and inhibited by the CB1 antagonist AM251 (HY-15443) and Cannabidiol. As a CB1 antagonist, 2-Linoleoyl glycerol does not enhance, but only attenuates, the activity of the CB1/CB2 receptor ligands cannabinoids (AEA) and 2-arachidonoylglycerol (2-AG) ^[2].

Cat. No.	Product Name		Classification

HY-155481

CB2 receptor antagonist 3		Azide
CB2 receptor antagonist 3 (compound (S)-1) is an inverse agonist of the cannabinoid receptor CB2R with Kd=39 nM. CB2 receptor antagonist 3 can be used as a tool to synthesize a variety of CB2R probes .

HY-155481A

CB2 receptor antagonist 4		Azide
CB2 receptor antagonist 4 (compound (R)-1) is a *CB2R*-selective inverse agonist with a K_d value of 39 nM .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

CB2+receptor

Inhibitors & Agonists

Biochemical Assay Reagents

NaturalProducts

Isotope-Labeled Compounds

Click Chemistry

Natural
Products